Hur Jeongsoo, Park Inae, Lim Kyung Min, Doh Junsang, Cho Ssang-Goo, Chung Aram J
School of Biomedical Engineering, Korea University, Seoul 02841, Republic of Korea.
School of Interdisciplinary Bioscience and Bioengineering (I-Bio), Pohang University of Science and Technology (POSTECH), Pohang 37673, Republic of Korea.
ACS Nano. 2020 Nov 24;14(11):15094-15106. doi: 10.1021/acsnano.0c05169. Epub 2020 Oct 9.
Cell therapy and cellular engineering begin with internalizing synthetic biomolecules and functional nanomaterials into primary cells. Conventionally, electroporation, lipofection, or viral transduction has been used; however, these are limited by their cytotoxicity, low scalability, cost, and/or preparation complexity, especially in primary cells. Thus, a universal intracellular delivery method that outperforms the existing methods must be established. Here, we present a versatile intracellular delivery platform that leverages intrinsic inertial flow developed in a T-junction microchannel with a cavity. The elongational recirculating flows exerted in the channel substantially stretch the cells, creating discontinuities on cell membranes, thereby enabling highly effective internalization of nanomaterials, such as plasmid DNA (7.9 kbp), mRNA, siRNA, quantum dots, and large nanoparticles (300 nm), into different cell types, including hard-to-transfect primary stem and immune cells. We identified that the internalization mechanism of external cargos during the cell elongation-restoration process is achieved by both passive diffusion and convection-based rapid solution exchange across the cell membrane. Using fluidic cell mechanoporation, we demonstrated a transfection yield superior to that of other state-of-the-art microfluidic platforms as well as current benchtop techniques, including lipofectamine and electroporation. In summary, the intracellular delivery platform developed in the present study enables a high delivery efficiency (up to 98%), easy operation (single-step), low material cost (<$1), high scalability (1 × 10 cells/min), minimal cell perturbation (up to 90%), and cell type/cargo insensitive delivery, providing a practical and robust approach anticipated to critically impact cell-based research.
细胞疗法和细胞工程始于将合成生物分子和功能性纳米材料内化到原代细胞中。传统上,人们使用电穿孔、脂质转染或病毒转导;然而,这些方法受到细胞毒性、低可扩展性、成本和/或制备复杂性的限制,尤其是在原代细胞中。因此,必须建立一种优于现有方法的通用细胞内递送方法。在此,我们展示了一种多功能细胞内递送平台,该平台利用在带有腔室的T型微通道中产生的固有惯性流。通道中施加的拉伸再循环流极大地拉伸细胞,在细胞膜上产生不连续性,从而使纳米材料,如质粒DNA(7.9千碱基对)、信使核糖核酸、小干扰核糖核酸、量子点和大纳米颗粒(300纳米),能够高效内化到不同类型的细胞中,包括难以转染的原代干细胞和免疫细胞。我们确定,在细胞拉伸恢复过程中,外部货物的内化机制是通过被动扩散和基于对流的快速溶液跨细胞膜交换实现的。使用流体细胞机械穿孔,我们证明了转染率优于其他先进的微流控平台以及当前的台式技术,包括脂质体转染试剂和电穿孔。总之,本研究开发的细胞内递送平台具有高递送效率(高达98%)、操作简便(单步)、材料成本低(<1美元)、高可扩展性(1×10个细胞/分钟)、最小的细胞扰动(高达90%)以及对细胞类型/货物不敏感的递送等优点,提供了一种实用且强大的方法,有望对基于细胞的研究产生重大影响。